WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Boehringer Ingelheim

Boehringer IngelheimThe Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

www.boehringer-ingelheim.com

Boehringer Ingelheim RSS Channel

Filters
List of articles in category Boehringer Ingelheim
Title Published Date
Boehringer Ingelheim and Micromet announce global collaboration for multiple myeloma BiTE antibody 06 May 2010
Boehringer Ingelheim grows faster than the pharmaceutical market 29 April 2010
Boehringer Ingelheim launches Global Venture Fund to foster innovation in life sciences 06 April 2010
Dabigatran etexilate shows greater reductions than warfarin 30 March 2010
Boehringer Ingelheim Animal Health closes deal to acquire Animal Health Business from Pfizer 28 October 2009
FDA approves Micardis® (telmisartan) as the first treatment in its class 20 October 2009
Access to HIV medication 08 October 2009
New data show patients with chronic low back pain maintained pain reduction on duloxetine 14 September 2009
Boehringer Ingelheim to commence Phase III study investigating the role of BIBW 2992 (Tovok) 10 August 2009
Good first six months in 2009 for Boehringer Ingelheim 30 July 2009
Boehringer Ingelheim and Vitae Pharmaceuticals announce a major collaboration 17 June 2009
Boehringer Ingelheim and DeveloGen AG announce agreement 15 May 2009
Outcome of new Mirapexin®/Sifrol® (pramipexole) study 04 May 2009
New diagnostic tool for Hypoactive Sexual Desire Disorder (HSDD) in women 04 March 2009
European CHMP adopts negative opinion on Cymbalta for the treatment of fibromyalgia 27 October 2008
ERS COPD Research Award 2008 sponsored by Boehringer Ingelheim 08 October 2008
Boehringer Ingelheim signs a license agreement with Evec Inc. for its fully-human antibody programme 03 October 2008
TRANSCEND® trial confirms long-term protective benefits and excellent tolerability profile 03 September 2008
Boehringer Ingelheim continued to post strong growth in local currencies in the first half of 2008 11 August 2008
Closure of the tipranavir trials SPRING and TICINO 06 August 2008
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • Next
  • End

Business & Industry

  • GSK completes acquisition of Sierra Oncology
  • Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
  • Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
  • New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
  • Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron

Research & Development

  • Inhalable COVID-19 vaccine shows promise in rodent model
  • Researchers discover new leukemia-killing compounds
  • Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
  • Biomarkers found that could be drug targets against a deadly form of brain cancer
  • COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
  • Novel drug combo activates natural killer cell immunity to destroy cancer cells
  • Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Boehringer Ingelheim
  4. A healthy 2019: Four paws for more relaxation and exercise

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.